Is Salesforce or ServiceNow a Better Stock to Buy Right Now?

Salesforce reported fiscal Q1 2027 revenue of $11.1B, up 13% year over year, with adjusted operating margin expanding to 34.8% and Agentforce ARR surpassing $1B, but full-year revenue guidance implies only about 11% growth and includes roughly $8B of inorganic contribution from Informatica. ServiceNow delivered faster growth, with Q1 2026 revenue up 22% to $3.77B and free cash flow of $1.67B, while AI-related spending momentum remains strong. The article argues ServiceNow is the better business despite trading at about 67x earnings versus Salesforce at about 22x.

Analysis

The key second-order read-through is not simply that NOW deserves a premium, but that its monetization mix is structurally less exposed to the AI “seat compression” threat that is pressuring the broader enterprise stack. If AI agents reduce human logins and license counts, workflow and consumption-linked platforms should retain pricing power better than seat-based CRM tools; that makes NOW a relative winner inside software even if absolute multiples stay rich. The implication is broader than these two names: adjacent vendors tied to ticketing, IT ops, security orchestration, and process automation should see relatively better retention of wallet share than collaboration or front-office apps with more direct seat exposure.

The market is likely underappreciating how much of the current re-rating debate is really a duration problem, not a growth problem. CRM can still be a credible cash compounder, but its upside is constrained until organic growth re-accelerates without acquisition lift; that is a multi-quarter proof point, not a next-quarter catalyst. By contrast, NOW’s operating leverage and enterprise AI attach rates create a cleaner path to sustained multiple support, but the stock already discounts a lot of that success, so any deceleration in large-deal conversion or AI spend normalization could compress the multiple quickly over the next 3-6 months.

Contrarian angle: the consensus may be overpaying for “AI-proof” business models just as AI spend is still in an experimentation-to-deployment transition. If customers are pulling forward platform consolidation, CRM could surprise on cross-sell and workflow adjacency once AI features become embedded in core workflows, while NOW’s premium could be vulnerable if buyers shift from pilot budgets to procurement scrutiny. The most interesting setup may be relative rather than outright: the spread between a cheaper, slower compounder and a higher-quality, faster compounder is wide enough to express a mean-reversion trade if growth differentials stabilize.

Key Decisions for Investors

• Long NOW / short CRM pair trade over 3-6 months: own the higher-quality consumption-linked model and hedge sector beta; target continued multiple divergence if NOW sustains >20% growth while CRM remains low-teens.
• For accounts willing to own quality at a price, accumulate NOW on 5-10% pullbacks with a 6-12 month horizon; risk/reward improves only if the multiple resets toward the low-60s P/E on any AI spend wobble.
• Initiate a tactical short-dated call spread on CRM only if the stock pops on AI narrative headlines: upside is capped until organic growth inflects, making near-term rallies vulnerable to fade over 1-2 quarters.
• Use INFA as a secondary watchlist indicator rather than a primary long: if integration synergies disappoint or deal scrutiny rises, CRM’s reported growth support may fade faster than expected.
• If you need software exposure but want less AI seat-risk, rotate incremental capital from front-office SaaS into workflow/infrastructure names over the next quarter; NOW is the cleanest large-cap expression.